
The Uromigos
The UromigosAudio
- Format:
- Podcast
- New episodes:
- Daily
- Typical length:
- about 40 minutes
- Latest episode:
About this show
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Covers: oncology, genitourinary cancer, renal cell carcinoma, prostate cancer, bladder cancer, antibody drug conjugates, cancer immunotherapy, circulating tumor dna
Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
The Uromigos is a podcast on the latest developments in genitourinary cancer, hosted by Brian Rini and Tom Powles. Recent episodes cover T cell engagers in kidney cancer, doublet therapy in renal cell carcinoma, prostate cancer sequencing, and antibody drug conjugates and ctDNA in bladder cancer.
Cosmos
Similar in subject
- BackTable Urology
Both cover: bladder cancer, prostate cancer - Oncology Brothers: Practice-Changing Cancer Discussions
Both cover: genitourinary cancer, oncology - Two Onc Docs
Both cover: prostate cancer, oncology
Similar shows
Explore more
Episodes
Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)
· 35 min
Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.
Not rated yetEpisode 498: APCCC 2026 - mCRPC
· 21 min
This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-driven therapy, and emerging treatment options.
Not rated yetEpisode 497: Reflections on the capivasertib ODAC
· 21 min
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.
Not rated yetEpisode 496: APCCC 2026 - mHSPC Landscape
· 26 min
Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
Not rated yetEpisode 495: APCCC 2026 - Locally-advanced Prostate Cancer
· 31 min
This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment decisions.
Not rated yetEpisode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist
· 40 min
Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.
Not rated yetEpisode 493: The Role of Chemotherapy in mHSPC
· 47 min
In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights shared during a recent conversation with Dr. Deepak Kilari, a GU Medical Oncologist, exploring the nuances of chemotherapy in this context. We discuss key trials, shifting definitions of disease volume, and the implications for treatment decisions.
Not rated yetEpisode 492: Novel Biomarkers and Targets in Germ Cell Tumors
· 33 min
This podcast features Dr. Mike Glover from MDACC discussing recent advances in germ cell tumor research, focusing on novel biomarkers like microRNA and ctDNA, and emerging therapies targeting Claudin-6. The conversation explores how these innovations could transform diagnosis, prognosis, and treatment strategies.
Not rated yetEpisode 490: Systemic Therapy Only in Patients wtih MIBC
· 48 min
Laura Bukavina, Tyler Stewart and Amanda Nizam join Brian and Tom to discuss and debate a new clinical trial exploring EVP in MIBC with omission of cystectomy of clinical CR patients
Not rated yetEpisode 489: Live Podcast From EAU
· 48 min
Tom and Brian take the stage in London for a live podcast. With the help of several special guests from the audience, they discuss management of peri-operative therapy in bladder cancer (notably in patients who may refuse cystectomy) and also the emerging pembro plus belzutifan data in adjuvant RCC.
Not rated yet